From the Journals

Psychiatrists’ views on psychoactive drugs clash with U.S. policy


 

FROM THE INTERNATIONAL JOURNAL OF DRUG POLICY

Therapeutic value, abuse potential

Participants were asked to rate the safety, therapeutic value, and abuse potential of the four drugs as well as alcohol, a nonscheduled legal drug, if used properly or as directed.

Respondents viewed psilocybin and ketamine as similarly safe – and safer than methamphetamine and alprazolam. They considered ketamine as having the highest therapeutic potential, followed by psilocybin, and then alprazolam and methamphetamine. “Last was alcohol, which we expected because alcohol is not used therapeutically,” said Dr. Levin.

Survey completers viewed methamphetamine, alprazolam, and alcohol as having similarly high abuse potential, and ketamine as having mid-level abuse potential. Psilocybin was rated as having the lowest abuse potential, “which is exactly the opposite of what is implied by its schedule I status,” noted Dr. Levin.

The results provide evidence these drugs “are incorrectly scheduled,” he said.

“This suggests the schedule does not reflect current evidence, which I think is really important to understand because there are consequences to the drug schedule,” including criminal justice and research consequences, he added.

Dr. Levin pointed out that possession of drugs in more harmful schedules is linked to sometimes lengthy prison sentences.

The psychiatrists’ perceptions of the drugs “overlaps pretty significantly” with recent surveys of other mental health professionals, including psychologists and addiction experts, he noted.

The study was funded by the Drug Enforcement and Policy Center, Moritz College of Law, and The Ohio State University. Dr. Levin reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

‘Go Ask Alice’: A fake view of teen mental health
MDedge Family Medicine
HCV reinfection uncommon among people who inject drugs
MDedge Family Medicine
‘Shocking’ and persistent gap in treatment for opioid addiction
MDedge Family Medicine
Patients who engage in risky ‘chemsex’ benefit from appropriate treatment
MDedge Family Medicine
Reducing alcohol intake may reduce cancer risk
MDedge Family Medicine
Psychedelic drug therapy a potential ‘breakthrough’ for alcohol dependence
MDedge Family Medicine
Stable, long-term opioid therapy safer than tapering?
MDedge Family Medicine
Alcohol warning labels need updates to reflect harms: NEJM
MDedge Family Medicine
DOJ: Indiana nurses allowed controlled substances during opioid recovery
MDedge Family Medicine
How to identify and treat patients with substance use disorders
MDedge Family Medicine